Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

Abstract: The present disclosure relates to compounds of formula (I): which are inhibitors of p38 mitogen-activated protein kinase enzymes, particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.

Abstract: There is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, including all tautomers thereof, compositions comprising the same, use of said compound and compositions for treatment, in particular for the treatment of asthma and COPD, and processes for the preparation of said compound.

Abstract: The present invention relates inter alia to the treatment or prevention of influenza virus infection (including subtypes influenza A virus, influenza B virus, avian strain H5N1, A/H1N1, H3N2 and/or pandemic influenza) using compounds which inhibit the activity of p59-HCK and to a method of screening for a candidate drug substance intended to prevent or treat influenza virus infection in a subject, said method comprising identifying a test substance capable of inhibiting p59-HCK activity.

Abstract: The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

Abstract: The present invention relates to compositions comprising chitin microparticles and their medical uses, and in particular to compositions for use as vaccines which comprise antigen from an infectious agent, a chitin microparticle preparation, and a further adjuvant.

Abstract: We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

Abstract: The present disclosure relates to compounds of formula (I): which are inhibitors of p38 mitogen-activated protein kinase enzymes, particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD

Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof, which are inhibitors of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

Abstract: There is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, including all tautomers thereof, compositions comprising the same, use of said compound and compositions for treatment, in particular for the treatment of asthma and COPD, and processes for the preparation of said compound.

Abstract: There are provided inter alia compounds of formula (I) wherein R1, Ar, L, X, R3 and Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.

Abstract: The present invention relates to pharmaceutical compositions and their uses in therapy. In particular, the invention relates to compositions comprising methotrexate, preferably wherein the compositions are for administration via the inhaled or intranasal route.

Abstract: A wireless broadband communications system that provides higher performance and increased spectral efficiency in point-to-point and point-to-multipoint applications. The wireless communications system includes a plurality of transceivers and a plurality of transmit and receive antennas. The system can be configured as a 1:n SIMO system that transmits and receives signals over a single channel of information flow, or an n:n MIMO system that transmits and receives signals over multiple channels of information flow, based upon channel state information and average vector error measurement values corresponding to the respective channels of information flow, which are determined by the system via an adaptive modulation technique.

Abstract: Methods of producing microparticles, and especially chitin microparticles (CMP), are disclosed that involve reducing the size of (larger) particles using a (high shear) microfluidising instrument.

Abstract: The present invention relates to chitin microparticles and their medical uses, in particular in the treatment of allergy, or the treatment of conditions that would benefit from an upregulation of the cell mediated immune system, or an up-regulation of natural killer (NK) cell activity and/or the secretion of interferon-? (IFN-?).

Abstract: The present invention relates to compositions comprising chitin microparticles and their medical uses, and in particular to compositions for use as vaccines which comprise antigen from an infectious agent, a chitin microparticle preparation, and a further adjuvant.

Abstract: The present invention relates to chitin microparticles and their medical uses, in particular in the treatment of allergy, or the treatment of conditions that would benefit from an upregulation of the cell mediated immune system, or an up-regulation of natural killer (NK) cell activity and/or the secretion of interferon-? (IFN-?).

Abstract: An earphone arrangement may be provided with at least one speaker arrangement including an earpiece adapted to be attached to the user's ear, and a speaker arranged in the earpiece so that the speaker faces the entrance of the ear canal of a user when the earpiece is operatively attached to the user's ear. The speaker arrangement may include an adjustment arrangement for adjusting the position of the speaker with respect to the earpiece, and thus the position of the speaker with respect to the entrance of the ear canal of the user when the earpiece is operatively attached to the user's ear.

Abstract: A wireless broadband communication system that operates with high efficiency and reduced latency in long range point-to-point and point-to-multipoint applications. The system includes multiple transceivers and multiple antennas for transmitting and receiving wireless signals using TDD techniques over multiple channels, which include a control channel for setting both the size of the transmit bursts and the modulation threshold level. By determining the size of the transmit bursts for a subsequent data transmission based upon the number of filler packets detected in a specified number of previously received bursts, and adjusting the modulation threshold level for the subsequent transmission based upon the transmit burst size, the system provides increased data throughput, while maintaining the packet error rate at an acceptable level. As the throughput requirements of the system are relaxed, the modulation threshold levels can be adjusted to provide reduced packet error rates.